GO:0030207 chondroitin sulfate proteoglycan catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030207 describes the biological process that breaks down chondroitin sulfate proteoglycans (CSPGs), which are core proteins carrying chondroitin sulfate glycosaminoglycan chains made of repeating beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine units that can be O-sulfated.
• CSPG catabolism controls the turnover of extracellular matrix and cell-surface proteoglycans, influencing processes such as neural regeneration, amyloid precursor protein trafficking, and tumor microenvironment remodeling.
• CSPG4 (also known as NG2 or MCSP) is a widely studied chondroitin sulfate proteoglycan whose expression and sulfation state affect nerve regeneration and cancer progression.
• Dysregulated CSPG catabolism has been linked to glioma biology, melanoma growth, and impaired sympathetic nerve regeneration after myocardial infarction.
• Key experimental approaches to study GO:0030207 include CRISPR knockout of CSPG core proteins or sulfotransferases, knock-in of tagged proteoglycans, and biochemical assays measuring glycosaminoglycan chain degradation.
• Understanding CSPG catabolic pathways supports therapeutic strategies such as CAR-T and antibody-based targeting of CSPG4 in multiple tumor entities.
Description
Chondroitin sulfate proteoglycan catabolic process (GO:0030207) is the set of biochemical reactions that degrade chondroitin sulfate proteoglycans (CSPGs), a major class of extracellular matrix and cell-surface molecules. CSPGs consist of a core protein covalently linked to one or more chondroitin sulfate glycosaminoglycan chains, which are linear polymers of repeating beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine disaccharide units that may be O-sulfated. The catabolic process removes or shortens these chains and can also degrade the core protein, thereby regulating the abundance and function of CSPGs in tissues. Researchers study GO:0030207 because CSPG turnover is critical for tissue remodeling, neural plasticity, and disease progression. For example, chondroitin sulfate proteoglycan 4 (CSPG4) is a well-characterized CSPG that influences sympathetic nerve regeneration after myocardial infarction and is a target for cancer immunotherapy. The brain CSPG neurocan is implicated in neural development and injury responses. In addition, chondroitin sulfate chains on amyloid precursor protein affect its trans-Golgi-to-surface transport, linking CSPG metabolism to protein trafficking. This article summarizes the definition, mechanism, key genes, disease relevance, and experimental models for studying GO:0030207, with a focus on how CRISPR-based approaches can be used to dissect this catabolic process.
chondroitin sulfate proteoglycan catabolic process At A Glance
| GO ID | GO:0030207 |
|---|---|
| GO term | chondroitin sulfate proteoglycan catabolic process |
| Ontology | biological_process |
| Synonym | chondroitin sulfate breakdown; chondroitin sulfate catabolism; chondroitin sulfate degradation; chondroitin sulphate catabolic process; chondroitin sulphate catabolism |
| Major function | Breakdown of chondroitin sulfate proteoglycans, including cleavage of chondroitin sulfate glycosaminoglycan chains and core protein degradation |
| Substrate | Chondroitin sulfate proteoglycans composed of a core protein and chondroitin sulfate chains |
| Key structural unit | Repeating disaccharide beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, with possible O-sulfation |
| Related processes | Extracellular matrix turnover, neural regeneration, protein trafficking, tumor microenvironment remodeling |
| Disease relevance | Glioma, melanoma, impaired nerve regeneration, cancer immunotherapy targets |
What Is GO:0030207?
GO:0030207, chondroitin sulfate proteoglycan catabolic process, is defined as the chemical reactions and pathways that result in the breakdown of chondroitin sulfate proteoglycans. These molecules are composed of a core protein linked to a chondroitin sulfate glycosaminoglycan chain, which is built from repeating disaccharide units of beta-(1,4)-D-glucuronic acid and beta-(1,3)-N-acetyl-D-galactosamine, with possible O-sulfation on the N-acetyl-D-galactosamine residue. The catabolic process includes enzymatic cleavage of the glycosaminoglycan chains and proteolytic degradation of the core protein, leading to reduced CSPG levels or altered CSPG structure.
Why Is chondroitin sulfate proteoglycan catabolic process Important in Cell Biology?
GO:0030207 is important because the controlled degradation of chondroitin sulfate proteoglycans regulates fundamental biological processes, including extracellular matrix remodeling, cell signaling, and neural repair. CSPGs such as CSPG4 and neurocan are critical for nervous system development and regeneration, and their catabolism influences outcomes after injury. In cancer, CSPG4 expression and sulfation affect tumor growth and immune targeting, making CSPG catabolic pathways relevant to immunotherapy. Additionally, chondroitin sulfate chains on amyloid precursor protein modulate its intracellular transport, connecting CSPG metabolism to protein trafficking pathways. Thus, understanding GO:0030207 provides insights into tissue homeostasis and disease mechanisms.
• Regulates extracellular matrix turnover and tissue remodeling by controlling CSPG abundance.
• Influences neural regeneration, including sympathetic nerve regeneration after myocardial infarction.
• Modulates brain development and injury responses through CSPGs such as neurocan.
• Affects protein trafficking, as chondroitin sulfate on amyloid precursor protein influences its trans-Golgi-to-surface transport.
• Plays a role in cancer biology, with CSPG4 as a target in glioma, melanoma, and other tumors.
• Supports development of CAR-T and antibody-based immunotherapies targeting CSPG4.
• Provides a basis for understanding how sulfation patterns of CSPGs regulate cellular behavior.
• Offers experimental opportunities for CRISPR screens to identify genes controlling CSPG catabolism.
• Links to diseases such as glioma, melanoma, and myocardial infarction-related nerve damage.
• Helps explain how proteoglycan degradation contributes to both physiological and pathological states.
What Happens During chondroitin sulfate proteoglycan catabolic process?
Recognition and initial cleavage of chondroitin sulfate chains
In simple terms: The long sugar chains on CSPGs are first cut into smaller pieces.
The catabolic process begins with the recognition of chondroitin sulfate proteoglycans by extracellular or lysosomal enzymes. Chondroitin sulfate chains, composed of repeating disaccharide units, are cleaved by chondroitinases or related glycosidases. This step reduces the size of the glycosaminoglycan chains and can alter the interaction of CSPGs with other matrix components. Studies on CSPG4 and neurocan highlight the importance of chain structure in regulating biological functions.
Degradation of the core protein
In simple terms: After the sugar chains are trimmed, the protein backbone of the proteoglycan is broken down.
Following glycosaminoglycan cleavage, the core protein of the CSPG is subject to proteolytic degradation. Proteases in the extracellular space or in lysosomes can degrade the protein backbone, leading to complete breakdown of the proteoglycan. This step is essential for clearing CSPGs from tissues and for recycling their components. The turnover of CSPG4 and related proteoglycans has been studied in the context of nerve regeneration and tumor biology.
Sulfation-dependent regulation of catabolism
In simple terms: The pattern of sulfate groups on the sugar chains affects how quickly CSPGs are degraded.
The sulfation pattern of chondroitin sulfate chains, particularly 4-sulfation versus 6-sulfation, influences the susceptibility of CSPGs to enzymatic cleavage. For example, chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction, indicating that specific sulfation states can modulate catabolic processing and downstream biological effects. This regulation adds a layer of complexity to GO:0030207, as different sulfation patterns may recruit distinct enzymes or affect substrate recognition.
Intracellular trafficking and lysosomal degradation
In simple terms: Some CSPGs are taken into cells and degraded in lysosomes.
In addition to extracellular degradation, CSPGs can be internalized and delivered to lysosomes for catabolism. Chondroitin sulfate on amyloid precursor protein accelerates its trans-Golgi-to-surface transport, suggesting that CSPG processing intersects with intracellular trafficking pathways. Lysosomal enzymes then complete the breakdown of both the glycosaminoglycan chains and the core protein, linking GO:0030207 to endolysosomal function.
Consequences for cell signaling and matrix remodeling
In simple terms: Breaking down CSPGs changes how cells interact with their environment.
The catabolic process releases fragments that can have biological activity or remove inhibitory cues. CSPG degradation can promote axon growth, alter tumor cell behavior, and affect immune cell infiltration. CSPG4 targeting in CAR-T and antibody-based therapies exploits the presence of this proteoglycan on tumor cells, and its catabolism may influence therapeutic efficacy. Thus, GO:0030207 is tightly linked to cell signaling and tissue remodeling.
Key Genes Involved in GO:0030207 chondroitin sulfate proteoglycan catabolic process
The following genes and proteins are directly or indirectly involved in chondroitin sulfate proteoglycan catabolic process (GO:0030207), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSPG4 | Chondroitin sulfate proteoglycan 4 (NG2/MCSP); core protein subject to catabolism | Target for CAR-T and antibody therapy; regulates nerve regeneration and tumor growth |
| NCAN | Neurocan; brain chondroitin sulfate proteoglycan | Involved in neural development and injury; model for CSPG turnover |
| APP | Amyloid precursor protein; carries chondroitin sulfate chains | Chondroitin sulfate accelerates trans-Golgi-to-surface transport; links CSPG metabolism to trafficking |
| CHST3 | Carbohydrate sulfotransferase 3; adds sulfate to chondroitin | Sulfation pattern affects catabolism and function |
| CHST11 | Carbohydrate sulfotransferase 11; chondroitin 4-sulfotransferase | Modifies chondroitin sulfate chains, influencing degradation |
| CHST12 | Carbohydrate sulfotransferase 12; chondroitin 4-sulfotransferase | Potential regulator of CSPG sulfation and catabolism |
| CHST13 | Carbohydrate sulfotransferase 13; chondroitin 4-sulfotransferase | May affect CSPG chain structure and turnover |
| CHST14 | Carbohydrate sulfotransferase 14; dermatan 4-sulfotransferase | Related to chondroitin sulfate modification |
| CHST15 | Carbohydrate sulfotransferase 15; chondroitin 4-sulfotransferase | Involved in sulfation of chondroitin sulfate |
| ACAN | Aggrecan; major chondroitin sulfate proteoglycan in cartilage | Model for CSPG catabolism in matrix turnover |
| VCAN | Versican; chondroitin sulfate proteoglycan in extracellular matrix | Studied in tissue remodeling and cancer |
| BCAN | Brevican; brain chondroitin sulfate proteoglycan | Relevant to neural plasticity and catabolism |
| HAPLN1 | Hyaluronan and proteoglycan link protein 1 | Stabilizes CSPG aggregates; affects accessibility to degrading enzymes |
| MMP2 | Matrix metalloproteinase 2; degrades core proteins | Proteolytic cleavage of CSPG core proteins |
| MMP9 | Matrix metalloproteinase 9; degrades core proteins | Involved in extracellular matrix remodeling |
| ADAMTS4 | A disintegrin and metalloproteinase with thrombospondin motifs 4; aggrecanase | Cleaves CSPG core proteins such as aggrecan |
| ADAMTS5 | A disintegrin and metalloproteinase with thrombospondin motifs 5; aggrecanase | Major enzyme in CSPG degradation |
| CTSB | Cathepsin B; lysosomal protease | Degrades CSPG core proteins in lysosomes |
| CTSD | Cathepsin D; lysosomal protease | Participates in lysosomal CSPG catabolism |
How Is chondroitin sulfate proteoglycan catabolic process Regulated?
The chondroitin sulfate proteoglycan catabolic process is regulated at multiple levels, including the expression of sulfotransferases that determine chondroitin sulfate sulfation patterns, the availability of proteases and glycosidases, and intracellular trafficking pathways. For example, chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction, indicating that specific sulfation states can modulate catabolic processing and downstream biological effects. Chondroitin sulfate on amyloid precursor protein accelerates its trans-Golgi-to-surface transport, suggesting that CSPG processing intersects with intracellular trafficking pathways. Additionally, the presence of CSPG4 on tumor cells influences their susceptibility to immune targeting, and its catabolism may affect therapeutic efficacy.
chondroitin sulfate proteoglycan catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSPG4 | Glioma, melanoma, triple-negative breast cancer; target for CAR-T and antibody therapy | CSPG4 knockout or knock-in in tumor cell lines; CAR-T co-culture assays |
| NCAN | Neural development and injury; brain CSPG | Ncan knockout mice or neuronal cell models |
| APP | Alzheimer's disease-related protein trafficking; chondroitin sulfate modification | APP knock-in with altered chondroitin sulfate attachment sites |
| CHST3/CHST11 | Sulfation-dependent nerve regeneration and matrix remodeling | Sulfotransferase knockout or point mutant cell lines |
| MMP2/MMP9 | Extracellular matrix degradation in cancer and inflammation | MMP knockout or overexpression models |
CSPG catabolism in cancer
Chondroitin sulfate proteoglycan 4 (CSPG4) is overexpressed in several tumors, including gliomas and melanomas, and is a target for CAR-T cell therapy and antibody-based immunotherapy. The catabolic processing of CSPG4 may influence tumor cell surface availability and immune recognition. For example, CSPG4-targeting CAR-macrophages inhibit melanoma growth, and co-targeting B7-H3 and CSPG4 shows promise in triple-negative breast cancer. Thus, GO:0030207 is relevant to cancer immunotherapy.
CSPG catabolism in neural regeneration
Chondroitin sulfate proteoglycans, such as neurocan and CSPG4, are key regulators of neural regeneration. Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction, indicating that catabolic processing of CSPGs affects nerve repair. Neurocan is a brain CSPG involved in neural development and injury responses. Therefore, understanding GO:0030207 may inform strategies to promote neural regeneration.
CSPG catabolism and protein trafficking
Chondroitin sulfate on amyloid precursor protein accelerates its trans-Golgi-to-surface transport, linking CSPG metabolism to intracellular trafficking. This connection suggests that catabolic processing of CSPGs could influence amyloid precursor protein localization and function, with potential implications for neurodegenerative conditions.
From chondroitin sulfate proteoglycan catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CSPG4 affect tumor growth or immune targeting? | CSPG4 knockout in melanoma or glioma cell lines |
| How does chondroitin sulfate sulfation affect nerve regeneration? | Knock-in of specific sulfotransferase mutants or point mutations in CHST genes |
| What is the role of chondroitin sulfate on APP trafficking? | APP knock-in with tagged chondroitin sulfate attachment sites |
| Which proteases degrade CSPG core proteins? | Overexpression or knockout of MMPs, ADAMTSs, or cathepsins |
| Can CSPG catabolism be monitored in live cells? | Tagged CSPG4 or neurocan knock-in with fluorescent reporters |
| What genes regulate CSPG turnover? | CRISPR library screening in cells expressing CSPG4 or NCAN |
How to Study the chondroitin sulfate proteoglycan catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Core protein levels and cleavage products | Assessing CSPG4 or neurocan degradation |
| Glycosaminoglycan quantification | Total chondroitin sulfate content | Measuring catabolic activity in cell lysates |
| Mass spectrometry | Sulfation patterns and disaccharide composition | Characterizing chondroitin sulfate chains |
| Fluorescence microscopy | Subcellular localization and trafficking | Tracking tagged CSPGs like APP |
| CRISPR knockout screening | Gene requirements for CSPG catabolism | Identifying novel regulators |
| Co-immunoprecipitation | Protein-protein interactions | Finding enzymes that bind CSPGs |
| Enzyme activity assays | Protease or glycosidase activity | Measuring MMP or ADAMTS activity |
| RNA-seq | Transcriptional changes in catabolic genes | Profiling sulfotransferases and proteases |
Biochemical assays for CSPG degradation
Biochemical assays can measure the cleavage of chondroitin sulfate chains and core proteins using purified enzymes or cell lysates. These assays often employ gel electrophoresis, chromatography, or mass spectrometry to detect degradation products. Such methods have been used to study CSPG4 and neurocan turnover.
CRISPR-based genetic screens
CRISPR knockout or activation screens can identify genes that regulate chondroitin sulfate proteoglycan catabolic process. By targeting sulfotransferases, proteases, and glycosidases, researchers can uncover novel regulators. This approach is particularly useful for studying CSPG4-dependent phenotypes in cancer cells.
Imaging and trafficking studies
Fluorescence microscopy and live-cell imaging can track the localization and degradation of tagged CSPGs. For example, chondroitin sulfate on amyloid precursor protein accelerates its trans-Golgi-to-surface transport, which can be visualized using fluorescent tags. Similar approaches apply to CSPG4 and neurocan.
Proteomics and glycomics
Mass spectrometry-based proteomics and glycomics can characterize CSPG core proteins and their glycosaminoglycan chains, revealing changes in catabolism. These methods help identify sulfation patterns and degradation intermediates, as demonstrated in studies of CSPG4 sulfation.
How CRISPR Can Be Used to Study GO:0030207 chondroitin sulfate proteoglycan catabolic process
Knockout
CRISPR knockout of CSPG core proteins (e.g., CSPG4, NCAN) or catabolic enzymes (e.g., MMPs, ADAMTSs) can reveal their roles in chondroitin sulfate proteoglycan catabolic process. For example, CSPG4 knockout in tumor cells reduces CAR-T targeting efficacy, demonstrating its importance in immunotherapy.
Point Mutation
Point mutations can be introduced into sulfotransferases or protease active sites to dissect specific steps in CSPG catabolism. For instance, mutating sulfation sites on CSPG4 alters its 4,6 sulfation and affects nerve regeneration.
Knock-in
Knock-in of tagged CSPGs (e.g., fluorescently labeled CSPG4 or APP) allows real-time tracking of catabolic processing and trafficking. This approach has been used to study chondroitin sulfate-dependent APP transport.
Overexpression
Overexpression of CSPGs or their degrading enzymes can model gain-of-function states and assess effects on matrix remodeling and disease. For example, overexpression of CSPG4 in melanoma cells enhances tumor growth and immune evasion.
How EDITGENE Supports chondroitin sulfate proteoglycan catabolic process Research
Researchers studying chondroitin sulfate proteoglycan catabolic process-related genes often need to determine whether a candidate gene is causally involved in CSPG turnover, how specific mutations affect enzyme activity, or whether tagging a proteoglycan alters its trafficking. EDITGENE provides comprehensive CRISPR gene editing services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for chondroitin sulfate proteoglycan catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| HYAL1 Knockout HEK293 Cell Line | EDJ-KQ2118 | Human | 3373 | Details Get a Quote |
| GALNS Knockout HEK293 Cell Line | EDJ-KQ3354 | Human | 2588 | Details Get a Quote |
| GUSB Knockout HEK293 Cell Line | EDJ-KQ4034 | Human | 2990 | Details Get a Quote |
| HYAL4 Knockout HEK293 Cell Line | EDJ-KQ8065 | Human | 23553 | Details Get a Quote |
| HEXB Knockout HEK293 Cell Line | EDJ-KQ13743 | Human | 3074 | Details Get a Quote |
| ARSB Knockout HEK293 Cell Line | EDJ-KQ17901 | Human | 411 | Details Get a Quote |
| HYAL1 Knockout HeLa Cell Line | EDJ-KQ20959 | Human | 3373 | Details Get a Quote |
| ARSB Knockout A-549 Cell Line | EDJ-KQ24149 | Human | 411 | Details Get a Quote |
| ARSB Knockout HCT 116 Cell Line | EDJ-KQ24150 | Human | 411 | Details Get a Quote |
| ARSB Knockout HeLa Cell Line | EDJ-KQ24151 | Human | 411 | Details Get a Quote |
| GALNS Knockout A-549 Cell Line | EDJ-KQ25009 | Human | 2588 | Details Get a Quote |
| GALNS Knockout HCT 116 Cell Line | EDJ-KQ25010 | Human | 2588 | Details Get a Quote |
| GALNS Knockout HeLa Cell Line | EDJ-KQ25011 | Human | 2588 | Details Get a Quote |
| HYAL1 Knockout A-549 Cell Line | EDJ-KQ22258 | Human | 3373 | Details Get a Quote |
| HYAL1 Knockout HCT 116 Cell Line | EDJ-KQ22259 | Human | 3373 | Details Get a Quote |
Displaying Records 1 To 15 Of 24 Records
Frequently Asked Questions About chondroitin sulfate proteoglycan catabolic process
What is GO:0030207?
GO:0030207 is the Gene Ontology term for chondroitin sulfate proteoglycan catabolic process, the breakdown of proteoglycans that carry chondroitin sulfate chains.
What genes are involved in chondroitin sulfate proteoglycan catabolic process?
Key genes include CSPG4, NCAN, APP, sulfotransferases such as CHST3 and CHST11, proteases like MMP2 and MMP9, and ADAMTS family members.
What is the function of chondroitin sulfate proteoglycan catabolic process?
It degrades CSPGs to regulate extracellular matrix turnover, neural regeneration, protein trafficking, and tumor microenvironment remodeling.
How is chondroitin sulfate proteoglycan catabolic process regulated?
It is regulated by sulfation patterns of chondroitin sulfate chains, expression of degrading enzymes, and intracellular trafficking pathways.
What diseases are associated with chondroitin sulfate proteoglycan catabolic process?
Dysregulation is linked to glioma, melanoma, impaired nerve regeneration after myocardial infarction, and cancer immunotherapy resistance.
What is CSPG4 and how does it relate to GO:0030207?
CSPG4 is a chondroitin sulfate proteoglycan that is subject to catabolism and is a target for CAR-T and antibody therapies in various tumors.
How can CRISPR be used to study chondroitin sulfate proteoglycan catabolic process?
CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the roles of CSPG core proteins and degrading enzymes.
What methods measure chondroitin sulfate proteoglycan degradation?
Western blot, mass spectrometry, glycosaminoglycan quantification, and imaging are commonly used to measure CSPG catabolism.
What is the role of neurocan in CSPG catabolism?
Neurocan is a brain chondroitin sulfate proteoglycan involved in neural development and injury, serving as a model for CSPG turnover.
How does chondroitin sulfate affect amyloid precursor protein?
Chondroitin sulfate accelerates trans-Golgi-to-surface transport of amyloid precursor protein, linking CSPG metabolism to protein trafficking.
Conclusion
Chondroitin sulfate proteoglycan catabolic process (GO:0030207) is a fundamental biological process that controls the turnover of CSPGs, impacting neural regeneration, cancer progression, and protein trafficking. Key genes such as CSPG4, NCAN, and APP, along with sulfotransferases and proteases, orchestrate this catabolism. Understanding these pathways offers therapeutic opportunities, particularly in immunotherapy and regenerative medicine. EDITGENE provides advanced CRISPR tools to study and manipulate this process, supporting the development of new treatments.
References
- 1. Harrer DC et al.. 2019. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.. Int J Mol Sci 20(23) PMID: 31779130
- 2. Kurokawa T et al.. 2024. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.. Proc Jpn Acad Ser B Phys Biol Sci 100(5):293-308 PMID: 38735753
- 3. Stucchi S et al.. 2025. B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.. J Immunother Cancer 13(5) PMID: 40425233
- 4. Greiner D et al.. 2025. Human CSPG4-targeting CAR-macrophages inhibit melanoma growth.. Oncogene 44(22):1665-1677 PMID: 40082557
- 5. Blake MR et al.. 2022. Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction.. Elife 11 PMID: 35604022
- 6. Rauch U et al.. 2001. Neurocan: a brain chondroitin sulfate proteoglycan.. Cell Mol Life Sci 58(12-13):1842-56 PMID: 11766883
- 7. Schiffer D et al.. 2018. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.. Int J Mol Sci 19(9) PMID: 30213051
- 8. Mihov D et al.. 2015. Chondroitin Sulfate Accelerates Trans-Golgi-to-Surface Transport of Proteoglycan Amyloid Precursor Protein.. Traffic 16(8):853-70 PMID: 25951880
